A notable advancement in glucose care is emerging with the approval of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and provides a https://utherpeptidess.com/product/tirzepatide-45mg/